Waardenburg syndrome type 3

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:896OMIM:148820E70.3
Who is this for?
Show terms as
3Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Waardenburg syndrome type 3 (WS3), also known as Klein-Waardenburg syndrome, is a rare genetic disorder characterized by the combination of pigmentary abnormalities, sensorineural hearing loss, and musculoskeletal anomalies of the upper limbs. It is considered the most severe form within the Waardenburg syndrome spectrum. The condition results from mutations in the PAX3 gene located on chromosome 2q36, which plays a critical role in the development of neural crest-derived cells, including melanocytes and certain musculoskeletal structures. Key clinical features include dystopia canthorum (lateral displacement of the inner corners of the eyes), a broad nasal root, synophrys (confluent eyebrows), heterochromia iridis (different colored eyes) or brilliant blue eyes, white forelock or premature graying of the hair, and patchy skin depigmentation. The distinguishing feature of WS3 compared to other Waardenburg subtypes is the presence of upper limb abnormalities, which can range from hypoplasia of the limb muscles to contractures of the fingers (camptodactyly), syndactyly (fusion of fingers), or more severe limb reduction defects. Sensorineural hearing loss, which may be unilateral or bilateral and ranges from mild to profound, is present in a significant proportion of affected individuals. There is currently no cure for Waardenburg syndrome type 3. Management is supportive and multidisciplinary. Early identification and intervention for hearing loss, including hearing aids or cochlear implants, is essential for speech and language development. Orthopedic evaluation and management may be needed for upper limb anomalies. Dermatologic counseling regarding sun protection for depigmented skin areas and ophthalmologic monitoring are also recommended. Genetic counseling is important for affected families to understand recurrence risks.

Also known as:

Clinical phenotype terms— hover any for plain English:

AcrocyanosisHP:0001063TracheomalaciaHP:0002779Cutaneous finger syndactylyHP:0010554Tented upper lip vermilionHP:0010804White hairHP:0011364
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Waardenburg syndrome type 3.

View clinical trials →

No actively recruiting trials found for Waardenburg syndrome type 3 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Waardenburg syndrome type 3 community →

Specialists

3 foundView all specialists →
AP
Adrian Wells, PhD
Specialist
PI on 1 active trial
SP
Suchitra Krishnan-Sarin, PhD
Specialist
PI on 1 active trial
EP
Eleanor Leavens, PhD
OVERLAND PARK, KS
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Waardenburg syndrome type 3.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Waardenburg syndrome type 3Forum →

No community posts yet. Be the first to share your experience with Waardenburg syndrome type 3.

Start the conversation →

Latest news about Waardenburg syndrome type 3

No recent news articles for Waardenburg syndrome type 3.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Waardenburg syndrome type 3

What is Waardenburg syndrome type 3?

Waardenburg syndrome type 3 (WS3), also known as Klein-Waardenburg syndrome, is a rare genetic disorder characterized by the combination of pigmentary abnormalities, sensorineural hearing loss, and musculoskeletal anomalies of the upper limbs. It is considered the most severe form within the Waardenburg syndrome spectrum. The condition results from mutations in the PAX3 gene located on chromosome 2q36, which plays a critical role in the development of neural crest-derived cells, including melanocytes and certain musculoskeletal structures. Key clinical features include dystopia canthorum (lat

How is Waardenburg syndrome type 3 inherited?

Waardenburg syndrome type 3 follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Waardenburg syndrome type 3 typically begin?

Typical onset of Waardenburg syndrome type 3 is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Waardenburg syndrome type 3?

3 specialists and care centers treating Waardenburg syndrome type 3 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.